KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Equity (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Return on Equity for 15 consecutive years, with 1.15% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 6.0% to 1.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.15%, a 6.0% increase, with the full-year FY2025 number at 1.54%, down 45.0% from a year prior.
  • Return on Equity was 1.15% for Q4 2025 at Halozyme Therapeutics, down from 1.42% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 2.44% in Q2 2021 to a low of 0.25% in Q2 2022.
  • A 5-year average of 1.31% and a median of 1.32% in 2023 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: surged 293bps in 2021, then crashed -219bps in 2022.
  • Halozyme Therapeutics' Return on Equity stood at 0.44% in 2021, then soared by 242bps to 1.52% in 2022, then increased by 12bps to 1.69% in 2023, then tumbled by -36bps to 1.09% in 2024, then grew by 5bps to 1.15% in 2025.
  • Per Business Quant, the three most recent readings for HALO's Return on Equity are 1.15% (Q4 2025), 1.42% (Q3 2025), and 1.37% (Q2 2025).